SPINAL AND BULBAR MUSCULAR ATROPHY
Clinical trials for SPINAL AND BULBAR MUSCULAR ATROPHY explained in plain language.
Never miss a new study
Get alerted when new SPINAL AND BULBAR MUSCULAR ATROPHY trials appear
Sign up with your email to follow new studies for SPINAL AND BULBAR MUSCULAR ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Leuprorelin's Long-Term effects in rare muscle disease
Disease control Recruiting nowThis study is monitoring the long-term safety and effectiveness of the drug leuprorelin in people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Researchers will follow about 1,890 patients in routine medical care for up to 8 years, tracking side…
Matched conditions: SPINAL AND BULBAR MUSCULAR ATROPHY
Sponsor: Takeda • Aim: Disease control
Last updated May 15, 2026 12:06 UTC
-
Scientists track muscle decline in rare nerve disease to pave way for future treatments
Knowledge-focused Recruiting nowThis study aims to find better ways to measure how spinal and bulbar muscular atrophy (SBMA) progresses. Researchers will follow 70 men with and without SBMA for up to 2 years, using muscle tests, imaging scans, and lab tests. The goal is to identify reliable markers of disease c…
Matched conditions: SPINAL AND BULBAR MUSCULAR ATROPHY
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated May 17, 2026 02:39 UTC